ZA200807380B - 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists - Google Patents

2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists

Info

Publication number: ZA200807380B
Authority: ZA; South Africa
Prior art keywords: prostaglandin; pyrimidine; substituted; receptor antagonists; monosubstituted amino
Prior art date: 2006-04-12

Application number

ZA200807380A

Other languages

English (en)

Inventor

Stefany David

Harris Keith John

Gillespy Timothy Alan

Charles J Gardner

Joacy C Aguiar

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-12

Filing date

2008-08-27

Publication date

2009-05-27

2008-08-27 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2009-05-27 Publication of ZA200807380B publication Critical patent/ZA200807380B/xx

Links

102000009389 Prostaglandin D receptors Human genes 0.000 title 1
108050000258 Prostaglandin D receptors Proteins 0.000 title 1
150000005005 aminopyrimidines Chemical class 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)

ZA200807380A 2006-04-12 2008-08-27 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists ZA200807380B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US74467606P	2006-04-12	2006-04-12

Publications (1)

Publication Number	Publication Date
ZA200807380B true ZA200807380B (en)	2009-05-27

Family

ID=38294040

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200807380A ZA200807380B (en)	2006-04-12	2008-08-27	2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists

Country Status (25)

Country	Link
US (1)	US20090036469A1 (fr)
EP (1)	EP2010503A1 (fr)
JP (1)	JP2009533473A (fr)
KR (1)	KR20080108287A (fr)
CN (1)	CN101421252B (fr)
AR (1)	AR060403A1 (fr)
AU (1)	AU2007238052B2 (fr)
BR (1)	BRPI0710710A2 (fr)
CA (1)	CA2649083C (fr)
CR (1)	CR10249A (fr)
DO (1)	DOP2007000068A (fr)
EC (1)	ECSP088813A (fr)
HN (1)	HN2008001530A (fr)
MA (1)	MA30409B1 (fr)
MX (1)	MX2008011369A (fr)
NO (1)	NO20084291L (fr)
NZ (1)	NZ571793A (fr)
PE (1)	PE20080186A1 (fr)
RU (1)	RU2431631C2 (fr)
TN (1)	TNSN08339A1 (fr)
TW (1)	TW200815395A (fr)
UA (1)	UA95950C2 (fr)
UY (1)	UY30283A1 (fr)
WO (1)	WO2007121280A1 (fr)
ZA (1)	ZA200807380B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5039594B2 (ja) *	2008-02-08	2012-10-03	株式会社日立ハイテクノロジーズ	レビュー装置，検査領域設定支援システム、および、欠陥の画像得方法
AR074776A1 (es) *	2008-12-18	2011-02-09	Sanofi Aventis	Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
CA2793223A1 (fr) *	2010-03-16	2011-09-22	Aventis Pharmaceuticals Inc.	Pyrimidines substituees en tant qu'antagonistes du recepteur d2 de prostaglandines
MX2012010038A (es) *	2010-03-16	2012-10-01	Aventis Pharma Inc	Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2.
CA2805452C (fr)	2010-07-05	2018-07-31	Actelion Pharmaceuticals Ltd	Derives d'heterocyclyle substitues par un 1-phenyle et leur utilisation en tant que modulateurs des recepteurs de la prostaglandine d2
EP2621276B1 (fr) *	2010-09-30	2017-12-27	Merck Sharp & Dohme Corp.	2-alcoxy pyrimidine inhibiteur de pde10
TW201331179A (zh)	2011-12-21	2013-08-01	Actelion Pharmaceuticals Ltd	雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途
EP2885307A1 (fr)	2012-07-05	2015-06-24	Actelion Pharmaceuticals Ltd.	Dérivés hétérocyclylés 1-phényl-substitués et leur utilisation en tant que modulateurs du récepteur de la prostaglandine d2
EP2912458B1 (fr)	2012-10-24	2018-07-18	NYU Winthrop Hospital	Biomarqueurs non-invasifs pour identifier les sujets à risque d'accouchement prématuré
CA2930008A1 (fr) *	2013-11-08	2015-05-14	Kissei Pharmaceutical Co., Ltd.	Derive de carboxymethylpiperidine
MY195016A (en)	2014-08-04	2023-01-03	Nuevolution As	Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
CR20180323A (es)	2015-11-20	2018-08-06	Idorsia Pharmaceuticals Ltd	Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EA201992676A1 (ru)	2017-05-18	2020-05-06	Идорсия Фармасьютиклз Лтд	Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en)	2017-05-18	2022-05-10	Idorsia Pharmaceuticals Ltd	Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
KR102612140B1 (ko)	2017-05-18	2023-12-08	이도르시아 파마슈티컬스 리미티드	피리미딘 유도체
AR111808A1 (es)	2017-05-18	2019-08-21	Idorsia Pharmaceuticals Ltd	Derivados de pirimidina como moduladores del receptor de pge2
KR20200109293A (ko)	2017-09-13	2020-09-22	프로제너티, 인크.	자간전증 바이오마커 및 관련된 시스템 및 방법
AU2020347662B2 (en) *	2019-09-13	2026-07-09	Meiji Co., Ltd.	Solid food and solid milk
WO2021113710A1 (fr)	2019-12-04	2021-06-10	Progenity, Inc.	Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
AU2020405446A1 (en)	2019-12-20	2022-05-26	Nuevolution A/S	Compounds active towards nuclear receptors
BR112022012205A2 (pt)	2019-12-20	2022-09-13	Nuevolution As	Compostos ativos para receptores nucleares
JP7713954B2 (ja)	2020-03-31	2025-07-28	ヌエヴォリューション・アクティーゼルスカブ	核内受容体に対して活性な化合物
CA3174252A1 (fr)	2020-03-31	2021-10-07	Nuevolution A/S	Composes actifs vis-a-vis des recepteurs nucleaires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3644799A1 (de) *	1986-06-04	1987-12-10	Hoechst Ag	Neue pyrimidin-derivate, deren herstellung und verwendung
US5047554A (en) *	1989-04-18	1991-09-10	Pfizer Inc.	3-substituted-2-oxindole derivatives
SE0200411D0 (sv) *	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
HN2005000795A (es) *	2004-10-15	2010-08-19	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200600457A (es) *	2005-10-13	2007-04-27	Aventis Pharma Inc	Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2

2007
- 2007-04-10 DO DO2007000068A patent/DOP2007000068A/es unknown
- 2007-04-10 AR ARP070101501A patent/AR060403A1/es not_active Application Discontinuation
- 2007-04-12 UA UAA200813109A patent/UA95950C2/ru unknown
- 2007-04-12 MX MX2008011369A patent/MX2008011369A/es active IP Right Grant
- 2007-04-12 NZ NZ571793A patent/NZ571793A/en not_active IP Right Cessation
- 2007-04-12 EP EP07760526A patent/EP2010503A1/fr not_active Withdrawn
- 2007-04-12 JP JP2009505615A patent/JP2009533473A/ja not_active Abandoned
- 2007-04-12 PE PE2007000450A patent/PE20080186A1/es not_active Application Discontinuation
- 2007-04-12 CN CN2007800127354A patent/CN101421252B/zh not_active Expired - Fee Related
- 2007-04-12 AU AU2007238052A patent/AU2007238052B2/en not_active Expired - Fee Related
- 2007-04-12 WO PCT/US2007/066481 patent/WO2007121280A1/fr not_active Ceased
- 2007-04-12 UY UY30283A patent/UY30283A1/es not_active Application Discontinuation
- 2007-04-12 TW TW096112790A patent/TW200815395A/zh unknown
- 2007-04-12 CA CA2649083A patent/CA2649083C/fr not_active Expired - Fee Related
- 2007-04-12 RU RU2008144578/04A patent/RU2431631C2/ru not_active IP Right Cessation
- 2007-04-12 KR KR1020087024764A patent/KR20080108287A/ko not_active Withdrawn
- 2007-04-12 BR BRPI0710710-2A patent/BRPI0710710A2/pt not_active IP Right Cessation
2008
- 2008-08-26 CR CR10249A patent/CR10249A/es not_active Application Discontinuation
- 2008-08-27 TN TNP2008000339A patent/TNSN08339A1/en unknown
- 2008-08-27 ZA ZA200807380A patent/ZA200807380B/xx unknown
- 2008-10-07 US US12/246,918 patent/US20090036469A1/en not_active Abandoned
- 2008-10-09 EC EC2008008813A patent/ECSP088813A/es unknown
- 2008-10-10 HN HN2008001530A patent/HN2008001530A/es unknown
- 2008-10-14 NO NO20084291A patent/NO20084291L/no not_active Application Discontinuation
- 2008-11-10 MA MA31375A patent/MA30409B1/fr unknown

Also Published As

Publication number	Publication date
CA2649083C (fr)	2011-06-28
MX2008011369A (es)	2008-09-18
JP2009533473A (ja)	2009-09-17
HK1131975A1 (en)	2010-02-12
WO2007121280A1 (fr)	2007-10-25
UA95950C2 (en)	2011-09-26
AU2007238052A1 (en)	2007-10-25
RU2431631C2 (ru)	2011-10-20
BRPI0710710A2 (pt)	2011-08-16
KR20080108287A (ko)	2008-12-12
MA30409B1 (fr)	2009-05-04
AU2007238052B2 (en)	2011-12-22
NZ571793A (en)	2011-08-26
AR060403A1 (es)	2008-06-11
UY30283A1 (es)	2007-11-30
CN101421252B (zh)	2011-10-12
TW200815395A (en)	2008-04-01
HN2008001530A (es)	2012-01-17
CN101421252A (zh)	2009-04-29
PE20080186A1 (es)	2008-04-15
ECSP088813A (es)	2008-11-27
NO20084291L (no)	2008-11-11
EP2010503A1 (fr)	2009-01-07
CR10249A (es)	2008-11-26
CA2649083A1 (fr)	2007-10-25
RU2008144578A (ru)	2010-05-20
US20090036469A1 (en)	2009-02-05
TNSN08339A1 (en)	2009-12-29
DOP2007000068A (es)	2007-10-31

Publication	Publication Date	Title
ZA200705449B (en)	2009-01-28	2-phenyl-indoles as prostaglandin D2 receptor antagonists
TWI372751B (en)	2012-09-21	Pyrimidines as prostaglandin d2 receptor antagonists
IL196587A0 (en)	2009-11-18	2-phenyl-indoles as prostaglandin d2 receptor antagonists
EP2099454A4 (fr)	2010-11-10	Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
ZA201001597B (en)	2012-09-29	Octahydropentalene compounds as chemokine receptor antagonists
IL198825A0 (en)	2010-02-17	Substituted diazepan compounds as orexin receptor antagonists
EP2058304A4 (fr)	2012-10-10	Antagoniste du récepteur p2x4
SI2094690T1 (sl)	2011-07-29	Derivati 2-aza-biciklo(3.1.0)heksana kot antagonisti receptorja za oreksin
ZA200800320B (en)	2009-02-25	Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
EP2184278A4 (fr)	2011-08-03	Antagoniste de récepteur p2x4
ZA200903334B (en)	2010-04-28	Substituted diazepan compounds as orexin receptor antagonists
IL190686A0 (en)	2008-11-03	Il-21 receptor antagonists
CR10249A (es)	2008-11-26	Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
IL198542A0 (en)	2010-02-17	2-aminoquinolines as 5-ht(5a)receptor antagonists
ZA201005179B (en)	2012-03-28	4-aminopyrimidine derivatives as histamine h4 receptor antagonists
ZA200903499B (en)	2010-03-31	Indoles which act as via receptor antagonists
EP2222676A4 (fr)	2011-10-26	Antagonistes des récepteurs de l'adénosine a1
ZA200802339B (en)	2009-10-28	Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
IL185640A0 (en)	2008-01-06	Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
ZA200810564B (en)	2009-11-25	2-phenyl-indoles as prostaglandin D2 receptor antagonists
HK1145605A (en)	2011-04-29	Octahydropentalene compounds as chemokine receptor antagonists
HK1143155A (en)	2010-12-24	8-azabicycloü3.2.1¨octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
GB0516617D0 (en)	2005-09-21	EP2 Receptor antagonists
HK1152719A (en)	2012-03-09	Somatostatin receptor 2 antagonists
GB0701632D0 (en)	2007-03-07	MET receptor antagonists